Stock screenerAll disclosures →
EDGAR →
TRVI
Conviction 40HealthcareScan · Thu, Sep 24, 2026Trevi Therapeutics, Inc. (TRVI) closed at $14.68 (+1.49%) on Sep 24, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 32, RS Rating 89, -24.7% from its 52-week high, +23.4% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
TRVI$14.68+1.49%
ResistanceSupportVol 14Insider sell3
Vol MA14 1.61M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price14.68
Change+1.49%
Gap-0.83%
Rel volume1.47×
Avg volume1.57M
Avg $ vol24.86M
SMA 2016.00
SMA 5017.26
SMA 20014.23
Price vs 50-15.00%
Price vs 200+3.13%
MA stackmixed
50/200 cross—
Supertrenddown · 16.38
RSI (14)32
MACD hist-0.12
MACD cross—
Stoch %K / %D20 / 15
ADX (14)30
+DI / −DI12 / 33
RSI divergence—
MACD divergence—
ATR %4.82%
ADR %4.13%
52w high19.50
52w low8.46
From 52w high-24.74%
Above 52w low+73.46%
New 52w highNo
SqueezeOff
Bollinger width24.78%
%B0.17
Donchian pos16.44%
Donchian high18.11
Donchian low14.00
AVWAP (52w high)17.36
vs AVWAP high-15.48%
AVWAP (52w low)14.01
vs AVWAP low+4.74%
OBV trendDown
Chaikin MF (20)-0.07
Today vs 20d1.47×
Avg vol (14d)1.61M
Avg vol (20d)1.57M
Avg $ vol (20d)24.86M
Market cap2.09B
RS Rating89 / 99
RS 3m (vs SPY)-22.96%
RS 6m (vs SPY)+11.46%
RS line new highNo
Trend template5/8
Technical rank50.5
1 week-3.52%
1 month-18.25%
3 months-18.47%
6 months+28.28%
1 year+75.12%
YTD+23.42%
P/E-48.90
P/B6.50
P/S—
P/FCF-49.66
EPS-0.3200
Div yield—
ROE-13.30%
ROA-12.94%
Debt/Eq—
Current37.28
EV/EBITDA-41.41
Gross margin—
Net margin—
Rev growth—
EPS growth10.75%
Price target29.00
Target upside97.61%
Analyst ratingBuy
Institutional109.18%
Ent. value2.04B
Revenue—
Net income-17.8M
Gross profit—
Free cash flow-42.1M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out141.98M
Employees34
ListedFri, May 3, 2019
Free float118.27M
Float %83.3%
Short interest12.01M
Days to cover8.0d
Short volume59.0%
Squeeze score65 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.11 vs −$0.11
Last surprise0.0% beat
Setup gradeD
Conviction40 / 100
Pattern quality—
Tech rank50.5 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance19.30
Support15.25
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Trevi Therapeutics stock trades at USD 14.71 as biotech data mattersAD HOC NEWS · Tue, Sep 22, 2026
Congress activity
Disclosed STOCK Act trades in TRVI
No recent disclosed trades by Congress in TRVI. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in TRVI · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Heffernan Michael Thomas Director · Common Stock · 2026-09-15 | Exercise | 18.42K | $56K | 2026-09-15 | 2026-09-17 |
Heffernan Michael Thomas Director · Common Stock · 2026-09-15 | Sell | 18.32K | $276K | 2026-09-15 | 2026-09-17 |
Heffernan Michael Thomas Director · Common Stock · 2026-09-15 | Sell | 100 | $2K | 2026-09-15 | 2026-09-17 |
Heffernan Michael Thomas Director · Common Stock · 2026-09-15 | Exercise | 21.05K | $70K | 2026-09-15 | 2026-09-17 |
Heffernan Michael Thomas Director · Common Stock · 2026-09-15 | Sell | 20.95K | $316K | 2026-09-15 | 2026-09-17 |
Heffernan Michael Thomas Director · Stock Option (right to buy) · 2026-09-15 | Exercise | 18.42K | — | 2026-09-15 | 2026-09-17 |
Heffernan Michael Thomas Director · Stock Option (right to buy) · 2026-09-15 | Exercise | 21.05K | — | 2026-09-15 | 2026-09-17 |
Meeker David P Director · Nonstatutory Stock Option (right to buy) · 2026-06-03 | Grant | 35K | $0 | 2026-06-03 | 2026-06-04 |
Mathers Edward T Director · Nonstatutory Stock Option (right to buy) · 2026-06-03 | Grant | 35K | $0 | 2026-06-03 | 2026-06-04 |
Colangelo Dominick Director · Nonstatutory Stock Option (right to buy) · 2026-06-03 | Grant | 35K | $0 | 2026-06-03 | 2026-06-04 |
SEC filings
EDGAR filings in TRVI · 5 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.